361167-81-9 Usage
Chemical structure
The compound has a complex structure that includes a benzothiophene ring, a nitro group, a carbonyl group, and a piperazine ring.
Potential pharmaceutical applications
Due to its ability to interact with biological receptors and enzymes, the compound may have potential pharmaceutical applications.
Serotonin receptor antagonist
The compound's structure suggests that it may have activity as a potential serotonin receptor antagonist.
Inhibition of enzymes
The compound may act as an inhibitor of enzymes involved in neurological and psychiatric disorders.
Further research and testing needed
To fully understand the pharmacological properties and potential uses of this compound, additional research and testing are required.
Nitro group
The presence of a nitro group in the compound may contribute to its potential pharmacological activity.
Carbonyl group
The carbonyl group is an essential part of the compound's structure and may play a role in its interaction with biological targets.
Piperazine ring
The piperazine ring is a common structural motif in many pharmaceutical compounds and may contribute to the compound's potential activity.
Benzothiophene ring
The benzothiophene ring is a heterocyclic aromatic ring that may provide structural stability and contribute to the compound's pharmacological properties.
Chemical reactivity
The compound's reactivity with other molecules, such as receptors or enzymes, may be influenced by its complex structure and functional groups.
Check Digit Verification of cas no
The CAS Registry Mumber 361167-81-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,6,1,1,6 and 7 respectively; the second part has 2 digits, 8 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 361167-81:
(8*3)+(7*6)+(6*1)+(5*1)+(4*6)+(3*7)+(2*8)+(1*1)=139
139 % 10 = 9
So 361167-81-9 is a valid CAS Registry Number.
361167-81-9Relevant articles and documents
6-(4-Chlorophenyl)-3-substituted-thieno[3,2-d]pyrimidin-4(3H)-one-based melanin-concentrating hormone receptor 1 antagonist
Tavares, Francis X.,Al-Barazanji, Kamal A.,Bishop, Michael J.,Britt, Christy S.,Carlton, David L.,Cooper, Joel P.,Feldman, Paul L.,Garrido, Dulce M.,Goetz, Aaron S.,Grizzle, Mary K.,Hertzog, Donald L.,Ignar, Diane M.,Lang, Daniel G.,McIntyre, Maggie S.,Ott, Ronda J.,Peat, Andrew J.,Zhou, Hui-Qiang
, p. 7108 - 7118 (2011/05/18)
Genetic manipulation studies in mice at both the MCH receptor 1 (MCHR1) as well as the MCH peptide levels have implicated MCHR1 as a key player in energy homeostasis. The phenotype exhibited by these studies, that is, increased metabolic rate, resistance to high fat diet, and subsequent weight loss, has spurred considerable efforts to develop antagonists of MCHR1. In continuation of efforts directed toward this goal, the present work capitalizes on the putative binding mode of an MCH antagonist, resulting in the identification of several novel chemotypes that are potent and selective MCHR1 antagonists. In addition, the favorable pharmacokinetics of representative examples has allowed for the evaluation of an MCHR1 antagonist in a high fat diet-induced obese rodent model of obesity. The tolerability of the right-hand side of the template for diverse chemotypes accompanied by favorable effects on weight loss enhances the attractiveness of this template in the pursuit toward development of effective anti-obesity agents.
